Valence Grade
Comparison6 min read

Ipamorelin vs CJC-1295: GHRP + GHRH Stack Rationale

Ipamorelin is a GHRP — it amplifies GH pulse magnitude. CJC-1295 is a GHRH analog — it provides the signal that initiates GH release. They work on different steps of the same pathway, which is why the stack produces significantly greater GH output than either alone.

Two Different Receptor Systems

Understanding why these peptides are complementary requires understanding how GH is regulated. GH release from pituitary somatotrophs is controlled by two opposing hypothalamic signals: GHRH (growth hormone releasing hormone) — stimulates GH synthesis and release. Somatostatin — inhibits GH release. Ghrelin (and GHRPs like ipamorelin) — acts on GHS-R1a receptors to amplify GH pulsatility. CJC-1295 acts on GHRH-R (the GHRH receptor). Ipamorelin acts on GHS-R1a (the ghrelin receptor). These are completely different receptor systems.

What GHRH Analogs Do: CJC-1295

CJC-1295 provides the GHRH signal — it tells somatotrophs to make and release GH. Without a GHRH signal, somatotrophs have limited stimulus to release GH. CJC-1295 with DAC extends this signal continuously for ~7 days via albumin binding. CJC-1295 without DAC (Mod GRF 1-29) provides a shorter, more pulse-like GHRH stimulus. Alone, CJC-1295 increases baseline GH and IGF-1 — but the magnitude of each GH pulse remains limited without concurrent GHRP activity.

What GHRPs Do: Ipamorelin

Ipamorelin amplifies the amplitude of GH pulses by agonizing the ghrelin receptor. It also antagonizes somatostatin signaling — reducing the inhibitory brake on GH release. Without a priming GHRH signal (CJC-1295), ipamorelin produces GH pulses, but from a lower baseline. With a GHRH signal already present, ipamorelin dramatically amplifies the pulse magnitude because the somatotrophs are already primed for release.

The Synergy: Two Levers, One Output

Combined, CJC-1295 and ipamorelin act on both regulatory mechanisms of GH release simultaneously: CJC-1295 primes somatotrophs via GHRH-R activation. Ipamorelin amplifies the pulse and reduces somatostatin inhibition via GHS-R1a. Published data show the combination produces significantly greater GH AUC (area under the curve) than either compound alone — not just additive, but synergistic, because both steps of the pathway are engaged simultaneously.

Choosing the Right CJC-1295 Form

CJC-1295 DAC: Used when sustained IGF-1 elevation is the research goal. Provides continuous GHRH stimulus; pair with ipamorelin injections for pulsatile amplification. CJC-1295 without DAC (Mod GRF 1-29): Used when mimicking natural pulsatile GHRH secretion is the priority. Co-inject with ipamorelin for synchronized GHRH + GHRP stimulus producing a single amplified GH pulse per injection event.

← Back to Research LibraryBrowse Products →